Here is the latest shareholding Pattern of LINK PHARMA. For more details, see the LINK PHARMA financial fact sheet and LINK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | |
Mutual Funds | % | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Financial institution/Banks/Insurance | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Government | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Institution | % | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Bodies Corporate | % | 5.95 | 5.96 | 6.07 | 5.95 | 6.16 | 6.34 | 6.34 | 6.04 | |
Individuals | % | 38.96 | 38.97 | 38.98 | 39.15 | 38.39 | 38.24 | 37.05 | 37.71 | |
NRIs/OCBs | % | 2.16 | 2.04 | 2.05 | 2.06 | 2.07 | 2.07 | 2.07 | 2.11 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 1.42 | 1.52 | 1.39 | 1.33 | 1.87 | 1.84 | 3.03 | 2.63 | |
Total Non-Institution | % | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | |
Total Public | % | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: CIPLA ZYDUS LIFESCIENCES DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
Asian share benchmarks fell on Thursday as markets digested the implications of policymakers in major economies preferring to take patient approach to monetary easing amid sticky inflation.